ZabBio

Executive Summary

ZabBio is a private biotechnology company headquartered in San Diego, focused on developing monoclonal antibody-based therapies for infectious diseases and reproductive health. Founded in 2015, the company aims to address significant unmet medical needs by leveraging antibody technology to create effective treatments. ZabBio's strategic emphasis on scalable, cost-efficient manufacturing is designed to ensure broad patient access, particularly in large, cost-sensitive markets. While the company has not disclosed a specific pipeline, its core mission suggests a focus on high-prevalence conditions where affordable biologic therapies could have substantial public health impact. As a private entity with limited public data, ZabBio's current stage of development remains unclear. The company's commitment to both innovation and affordability positions it uniquely in the biopharma landscape, but its lack of disclosed clinical programs or funding history introduces uncertainty. Success will depend on its ability to advance candidates through preclinical and clinical stages while securing partnerships or financing. Overall, ZabBio represents an early-stage opportunity with potential in niche antibody markets, but near-term visibility is low.

Upcoming Catalysts (preview)

• TBDDisclosure of lead antibody candidate and preclinical data40% success
• TBDAnnouncement of strategic partnership or licensing deal30% success